AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05411991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous bumetanide TID
Description: An intravenous bolus of bumetanide is administered TID, with dosing according to eGFR: 2 mg for an eGFR >45 mL/min/1.73m²; 3 mg for an eGFR 30-45 mL/min/1.73m²; and 4 mg for an eGFR \<30 mL/min/1.73m². At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), a dose of 4 mg TID is used.
Study NCT05052918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 1 hour of moderate-intensity aerobic exercise 3 days a week for 12 weeks
Study NCT05292053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
Description: TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)
Study NCT05758103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)
Description: Non-surgical professional mechanical debridement and probiotic supplement Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)
Study NCT03193242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Asthma Management System: eAMS
Description: Electronic Asthma Management System: eAMS Intervention~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe.
Study NCT06230172 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Weaning incubator (heat) at an lower postnatal weight
Description: Infants in the intervention group are weaned in the same manner as the infants in the control arm; however, the wean begins at a lower postnatal weight.~Our institutional guidelines for weaning infants from incubator to crib was unchanged for both groups.
Study NCT06507072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Rock Climbing Program
Description: Twelve week rock climbing program. The program will take place once per week over the course of twelve weeks.
Study NCT05411991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral chlorthalidone OD
Description: In case of hypernatremia (>145 mmol/L) or low eGFR (\<30 mL/min/1.73m²), oral chlorthalidone 50 mg OD is added to the diuretic treatment. At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), oral chlorthalidone is provided at a dose of 100 mg OD. Chlorthalidone is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L.
Study NCT05411991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous canrenoate 200 mg OD
Description: At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), intravenous canrenoate 200 mg OD is provided. Canrenoate is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L or if serum potassium levels are >5.5 mmol/L. If canrenoate is administered, oral mineralocorticoid receptor drugs are temporarily withhold until switch to oral diuretic treatment.
Study NCT05411991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance infusion
Description: A maintenance infusion with 500 mL dextrose 5% and 3 g MgSO4 is started at an infusion rate of 20 mL/h upon the moment of first protocol-specified administration of intravenous diuretics and continued until switch to oral diuretic therapy. 40 mmol KCl is added if serum potassium levels are \<4 mmol/L. In case of hypotonic hyponatremia with serum sodium concentration \<130 mmol/L, dextrose 5% will not be provided and MgSO4 will be administered in 50 mL of normal saline (NaCl 0.9%).
Study NCT05411991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral potassium supplements
Description: If serum potassium levels are \<3.5 mmol/L at any time during the administration of intravenous diuretics, oral potassium supplements are provided as needed to keep serum potassium levels >4 mmol/L
Study NCT05411991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous hypertonic saline
Description: In case of hypotonic hyponatremia with serum sodium concentration \<125 mmol/L, a bolus of 150 mL hypertonic saline 3% is administered and repeated OD if necessary, until sodium levels are ≥135 mmol/L.
Study NCT05411991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch to oral diuretic therapy
Description: Upon complete resolution of clinical signs of fluid overload with UNa \<80 mmol/L, intravenous diuretics are switched to an oral schedule including:~* Loop diuretics with dose \& frequency at the discretion of the treating physician~* Chlorthalidone 50 mg if added for diuretic resistance at any time during the intravenous diuretic phase~* Spironolactone 25 mg or another equivalent mineralocorticoid receptor antagonist
Study NCT05411991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual AHF care
Description: It is recommended to administer an intravenous loop diuretic dose at least BID (or through continuous infusion), with the aim of achieving a urine output 3-5 L per day until the patient is considered in an optimal volume status as is recommended by current guidelines.
Study NCT05401409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: 70mls beetroot juice (400mg nitrate) given daily for 4 weeks
Study NCT05401409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted beetroot juice
Description: 70mls beetroot juice (nitrate-depleted) given daily for 4 weeks
Study NCT04865107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
Study NCT04865107 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PlasmaLyte A and 5% Human Albumin
Study NCT05894863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart flex stent
Description: Smart flex stent will be used for femoropopliteal occlusive lesions.
Study NCT05720663 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: Participants will receive the standard of care for their condition
Study NCT04769102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: seat cushions
Description: flat versus contoured customized seat cushions
Study NCT05582759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: teleCBT-I + SH/ReadiWatchTM
Description: Participants receive real time feedback on sleep metrics, education on sleep hygiene and a four-week virtual cognitive behavioral therapy for insomnia intervention
Study NCT05582759 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SH/ReadiWatchTM
Description: Participants receive real time feedback on sleep metrics and education on sleep hygiene
Study NCT05206383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive message - placebo
Description: Subjects who will be told that the applied plastering method significantly increases muscle strength (positive message - placebo).
Study NCT05206383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative message - nocebo
Description: Subjects who will be told that the applied plastering method has no effect on muscle strength (negative message - nocebo).
Study NCT05206383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral message
Description: Subjects who will be told that the applied plastering method is currently under investigation and the investigators do not know its effects (neutral message).
Study NCT05597449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YouTube videos on care after urologic surgery
Description: Supplemental educational videos regarding care following pediatric urologic surgery
Study NCT05446142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib capsule formulation (CAP)
Description: A single encorafenib dose of the CAP formulation
Study NCT05446142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib first formulation
Description: first formulation
Study NCT05446142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib second formulation
Description: second formulation
Study NCT05446142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole tablet
Description: Proton-pump inhibitor
Study NCT05999591 — intervention group
Intervention type: PROCEDURE
Intervention: Intrauterine insemination
Description: Transfer of sperm into the fallopian tube through a specialised cannula
Study NCT04709653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupation-based nursing program
Description: First Session (Rug Weaving Activity): The child and the caregiver will be informed about the purpose and process of the research. The researcher will show in detail how to use rug weaving materials. Rug weaving activity will be started with the child. At the end of the 30-minute practice, the second session with the child will be planned and the session will be ended.~Second Session (Rug Weaving Event Continues). Third Session (Rug Weaving Activity Continues): Rug weaving activity will be completed and the session will be ended by planning the fourth session with the child.~Fourth Session (Origami Activity): A figure will be made with origami with the child. The child will be given support to make another figure. The fifth session hour will be planned with the child and the session will be ended.~Fifth Session (Shape Making Activity with Chenille): A shape will be created with the child with chenille.
Study NCT04709653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Routine nursing care
Study NCT05106205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5213 10mg
Description: single dose administration (one tablet once a day)
Study NCT05106205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5213-R 10mg
Description: single dose administration (one tablet once a day)
Study NCT06224777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5% Albumin (human) Solution
Description: Albumin is a biological product derived from human blood donors.
Study NCT06224777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paeds solution
Description: Paeds solution contains dextrose 4.3%, and Sodium Chloride 0.18%
Study NCT06224777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paeds solution
Description: Paeds solution contains dextrose 4.3%, and Sodium Chloride 0.18%
Study NCT06023251 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Nutrition
Description: Nutritional care plan implementation, including~* A step-up and step-down nutritional protocol guided by caloric and protein ratio~* Monitoring plan including daily nutritional intake assessment by a dietician and (para)medical supervision by a nutrition support pharmacist and nurse concerning dysphagia, refeeding syndrome, electrolytes abnormalities and access issues~* Indirect calorimetry measurements to assess metabolic needs and body impedance analysis to assess body composition on regular time points~* Dedicated and specialized dietician and nurse involvement~* Adaptive communication policy (translating to native language) and culturally appropriate food regimens and artificial nutrition.
Study NCT06462170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boost Original meal replacement shake
Description: One bottle of Boost Original meal replacement shake.
Study NCT05916053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: 50.000 IU of vitamin D supplementation was prescribed for deficient/insufficient participants for a 3 month period.
Study NCT06043492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: 10 x 2 min running at vVO2max, interspersed by 2 min recovery at 40% VO2max
Study NCT06043492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coninuous Running
Description: 40 min continuous running at lactate threshold
Study NCT06043492 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Trial
Description: The participants will perform only the baseline and post acute-training evaluations, without performing exercise
Study NCT05030571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DPMAS
Description: DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China)
Study NCT05030571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017.
Study NCT05030571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017.
Study NCT05912075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: prior to tolinapant (ASTX660) for 6 cycles over 12 weeks
Study NCT05912075 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy LCRT
Description: 50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday) for 5 weeks
Study NCT05912075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy
Study NCT05912075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOLINAPANT (ASTX660)
Description: starting from 14 days before the first dose of radiotherapy, for 10 weeks.
Study NCT05912075 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy SCRT
Description: total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)
Study NCT05912075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy
Study NCT05912075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.
Study NCT05437614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micropulse diode laser cyclophotocoagulation in treatment of refractory Glaucoma
Description: Treatment of refractory Glaucoma by Micropulse diode laser cyclophotocoagulation
Study NCT05437614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyclocryoablation in treatment of refractory Glaucoma
Description: Treatment of refractory Glaucoma by cyclocryoablation
Study NCT05446051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Mandarin Version of the electronic patient self-Reporting of Adverse-events (eRAPID-MV)
Description: Phase I Interventions：eRAPID-MV(TRAEs survey)
Study NCT05446051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the telephone triage decision support system (TTDSS)
Description: Phase I Interventions：TTDSS
Study NCT06480136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921 injection and adebrelimab injection
Description: The Treatment group receive SHR-A1921 injection combined with adebrelimab injection
Study NCT06253247 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: NanoChitosan impregnated Calcium Hydroxide
Description: NanoChitosan impregnated Calcium Hydroxide used as an intracanal medication fro 7 days
Study NCT06253247 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NanoChitosan impregnated Calcium Hydroxide
Description: NanoChitosan impregnated Calcium Hydroxide used as an intracanal medication fro 7 days
Study NCT06238219 — intervention group
Intervention type: DRUG
Intervention: Neuromuscular Blocking Agent
Description: Administration of any neuromuscular blocking agent for surgery under general anesthesia
Study NCT05573464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI HFO 320/14.4/9.6 μg
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate
Study NCT05573464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BGF MDI HFA 320/14.4/9.6 μg
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate
Study NCT04783233 — intervention group
Intervention type: BIOLOGICAL
Intervention: Chitosan succinamide
Description: Chitogel will be tested for suitability as a packing material in tympanoplasty surgery.
Study NCT04783233 — intervention group
Intervention type: BIOLOGICAL
Intervention: Gelfoam
Description: Gelfoam is the current packing material for tympanoplasty surgery.
Study NCT06551298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menggongzi Tibetan Tea Special Drink
Description: Menggongzi Tibetan Tea Special Drink (50ml/time, taken after breakfast and lunch)+Low fat diet
Study NCT06551298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium 20Mg Tab
Description: Atorvastatin Calcium Tablets (20mg, qn)+Low Fat Diet
Study NCT06551298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low fat diet
Description: Low fat diet
Study NCT06351553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation exclusively with radiofrequency
Description: The QDOT (Biosense Webster, Inc.) or TactiFlex (Abbott S.E.) catheters will be used. The ablation will be controlled by temperature, with a limit of 42ºC and a power target of 30-40W. A high-power strategy (90 W/4 seconds) can be used on the posterior wall when the QDOT catheter is used.
Study NCT06351553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation exclusively with pulsed field ablation
Description: The Sphere-9 catheter will be used (with biphasic and unipolar wave), with a duration per application of 5 seconds and a separation between lesions of 5-6mm. The target temperature increase will be at least 1.5ºC above the patient's basal temperature to mark the ablation as effective.
Study NCT06351553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined pulmonary vein isolation
Description: The Sphere-9 catheter will be used for both radiofrequency and pulsed field ablation. When using radiofrequency, the ablation will be temperature controlled, with a target temperature of 73ºC. The duration per application will be 5 seconds. Catheter irrigation during ablation will be 30ml/min, with a maximum current intensity of 3700mA, and a maximum current density of 13.6mA/mm2. The separation between lesions will be 7-8mm. Regarding pulsed field ablation, the characteristics will be those indicated in Pulmonary vein isolation exclusively with pulsed field ablation group.
Study NCT03613792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Opioid analgesic
Study NCT03613792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Opioid analgesic
Study NCT03613792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Benzodiazepine
Study NCT03613792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Analgesic
Study NCT05222204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel
Description: intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis
Study NCT05352880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum magnesium level, FEMg
Description: Blood (serum) for: Magnesium (Mg).Urea, creatinine. Calcium (ca), phosphorus (ph).Sodium (Na), potassium (k), chloride (CL).Fasting blood glucose, cholesterol, triglycerides. Intact PTH, 25OH vitamin D.uric acid, albumin. CBC.~Trough level of cyclosporine or tacrolimus. ii. Urine for:24 hour urinary: Mg, Ca, Ph, Cl and protein. Spot urine sample to calculate fractional excretion of Mg (FEmg)~. Detailed history taking, Thorough Systemic physical examination.
Study NCT04730401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma from COVID-19 donors
Description: Convalescent plasma from COVID-19 donors
Study NCT04730401 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent plasma from COVID-19 donors
Description: Convalescent plasma from COVID-19 donors
Study NCT04730401 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mL saline